← Markets

Hims & Hers Health, Inc.

HIMS · NYSE

Market closed$32.84$-0.840000 (-2.49%)After hours $32.65 · -0.58%

Key statistics

Previous close$33.68
Open$32.67
Day high$34.04
Day low$31.91
52-week high$70.43
52-week low$13.74
Market cap7.33B
Volume9.15M
Average volume21.77M
P/E ratio-328.40
Forward P/E—
EPS-0.10
Dividend yield0.00%

Market context

Why it moved

HIMS shares declined amid continued investor concern over the company's significantly expanded convertible debt offering and the resulting dilution risk, as the telehealth firm raised its debt raise to $350 million to fund its Eucalyptus acquisition and AI healthcare expansion, weighing on a stock that has already lost substantial value over the past year.

SubstackStocktwitsSimitreehcCatholiccultureInstagram

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Hims & Hers Health shares fell as a late-day disclosure that Chief Accounting Officer Irene Becklund will depart effective October 9 added to pre-existing selling pressure from profit-taking ahead of its August 10 Q2 earnings report. The healthcare sector also weighed on sentiment, with the XLV ETF closing lower and broader markets pressured by escalating U.S.-Iran tensions and a semiconductor-led tech selloff. Analysts remain divided — bulls cite the Novo Nordisk GLP-1 partnership, international expansion (+1,014% YoY), and raised FY2026 guidance, while bears point to margin compression, elevated short interest (~28%), and competitive risks in the weight-loss market.

-2.4941

July 17, 2026Hims & Hers Health tumbled sharply, giving back a significant portion of its recent gains amid investor anxiety over regulatory risk and a key upcoming FDA meeting on peptide compounding rules. The decline came as the company shifted its narrative toward peptides following its worst week in two months, while broader healthcare outperformed — UnitedHealth Group surged on strong Q2 earnings and Abbott jumped over 12% — highlighting the divergence between Hims' speculative growth profile and more established healthcare names. With elevated short interest near 28%, ongoing GLP-1 competitive pressure from rivals like Ro and Amazon Pharmacy, and margin uncertainty embedded in its raised FY2026 guidance, sentiment remains fragile despite analysts maintaining buy ratings citing the Novo Nordisk partnership and international expansion momentum.

-9.3893

July 16, 2026Hims & Hers Health surged nearly 6% as investors refocused on the company's peptide growth narrative ahead of key FDA advisory committee meetings scheduled for later in July, building on momentum from an after-hours rally the prior session. The telehealth platform is positioning peptides as a major revenue catalyst to offset GLP-1 competition pressures from Amazon Pharmacy and rival Ro, while broader healthcare sentiment received a tailwind from State Street and UBS both upgrading the sector on improving earnings outlooks and drug pipeline optimism.

5.7468

July 15, 2026Hims & Hers Health shares gained after logging their worst week in two months, with investor focus pivoting to peptides ahead of a key upcoming FDA advisory meeting. The company launched a new peptides campaign targeting the regulatory catalyst, while options activity remained bullish — call options made up over 74% of the prior session's volume. The broader healthcare sector faced headwinds from earnings-driven declines in Abbott and UHS, but a softer-than-expected June CPI print helped lift market sentiment and cushion the session.

2.2397

July 14, 2026Hims & Hers Health closed essentially flat as investors shifted focus to the upcoming FDA peptide advisory meeting on July 23-24, a key catalyst the market is watching closely. The stock logged its worst week in two months after falling ~6% on July 10th, pressured by analyst concerns over weaker-than-expected retention for oral Wegovy members and lingering uncertainty around the peptide opportunity — even as BofA raised its price target to $37 and Canaccord and Barclays hold targets of $40 and $39, respectively. In after-hours, shares slipped modestly alongside broader healthcare sector weakness tied to geopolitical-driven market risk-off sentiment.
July 11, 2026Hims & Hers Health fell roughly 3% on Thursday, underperforming the broader healthcare sector (XLV essentially flat) and the S&P 500, which edged modestly higher. Sources point to renewed investor concern over competition and execution risk in the GLP-1 market as the key overhang, with Wall Street divided on the stock's trajectory ahead of Q2 earnings. While credit card data from June suggests GLP-1 demand remains healthy and the company has expanded its platform with new partnerships and international launches, elevated short interest (~28%) and margin pressure concerns continue to weigh on sentiment.

-3.0183

July 10, 2026Hims & Hers Health fell nearly 2% on Thursday, underperforming the broader healthcare sector (XLV), as Wall Street remains divided on the telehealth company's growth trajectory. Bank of America recently raised its price target on HIMS to $37 (from $36) while maintaining a Neutral rating, reflecting cautious optimism around GLP-1 demand — credit card spending data from June suggests the weight-loss business remains healthy — but competition from Amazon Pharmacy and margin pressure continue to cloud the near-term outlook. The broader macro backdrop, including geopolitical tensions in the Middle East driving oil higher and reigniting inflation fears, added to selling pressure across risk assets.

-1.7189

July 9, 2026Hims & Hers Health closed essentially flat amid a broad market risk-off session triggered by President Trump declaring the U.S.-Iran ceasefire 'over,' which sent oil prices surging and weighed on equities broadly. Despite the macro headwinds, HIMS held relatively resilient compared to the wider market pullback, with healthcare as a sector continuing its recent outperformance streak. Investor focus remains on the company's evolving growth narrative — including its Novo Nordisk GLP-1 partnership, Testosterone Rx+ launch, and potential peptide compounding opportunities — as analysts debate whether the stock remains undervalued following its ~344% three-year run.

-0.2765

HIMS Investor Relations · July 17, 2026Hims & Hers Chief Accounting Officer, Irene Becklund, Announces Departure from the CompanyPluang · July 15, 2026Law firm investigates Hims & Hers for allegedly sharing users' private health data without consent.Stocktwits · May 19, 2026HIMS Stock Slips Overnight: Hims & Hers Bulks Up Debt Raise To $350M For Eucalyptus Buyout, AI PushBusiness Wire · May 18, 2026Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform InvestmentInvestor's Business Daily · May 12, 2026The Surprising Reason This Novo-Tied Telehealth Play ToppledHIMS Investor Relations · May 11, 2026Hims & Hers Health, Inc. Reports First Quarter 2026 Financial Results
Mt Newswire · July 17, 2026Hims & Hers Health Chief Accounting Officer to Step Down
Benzinga · July 9, 2026B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $37
Benzinga · July 1, 2026Here’s How Much You Would Have Made Owning Hims & Hers Health Stock In The Last 5 Years
Benzinga · July 1, 2026Hims & Hers Stock Surges as Analysts Lift Price Targets
Benzinga · July 1, 2026Hims & Hers Health’s Peptide Opportunity Tempered By FDA Recommendation, Says Analyst
Mt Newswire · July 1, 2026BofA Securities Adjusts Hims & Hers Health Price Target to $36 From $25, Maintains Neutral Rating
Benzinga · July 1, 2026Canaccord Genuity Maintains Buy on Hims & Hers Health, Raises Price Target to $40
Benzinga · July 1, 2026B of A Securities Maintains Neutral on Hims & Hers Health, Raises Price Target to $36

Peers

S&P 500SPX · $7,457.69-1.01%Teladoc Health, Inc.TDOC · $9.43-0.42%American Well CorporationAMWL · $13.23+20.82%LifeMD, Inc.LFMD · $4.15-7.78%Guardant Health, Inc.GH · $155.87+0.56%BrightSpring Health Services, Inc. Common StockBTSG · $70.69+3.71%DaVita Inc.DVA · $236.97+1.26%Chemed CorporationCHE · $510.03+1.70%Fresenius Medical Care AG & Co. KGaAFMS · $24.11+0.08%Quest Diagnostics IncorporatedDGX · $210.68+0.61%Labcorp Holdings Inc.LH · $283.36+0.50%CVS Health Corp.CVS · $107.47+0.91%